Special considerations for adolescent athletic and asthmatic patients

Jan C Wuestenfeld,1,2 Bernd Wolfarth1,21Department of Preventive and Rehabilitative Sports Medicine, Technical University Munich (TUM), Munich, Germany; 2Institute for Applied Training Science (IAT), Leipzig, GermanyAbstract: Asthma is defined as a chronic inflammatory disorder of the airways with b...

Full description

Saved in:
Bibliographic Details
Main Authors: Wuestenfeld JC (Author), Wolfarth B (Author)
Format: Book
Published: Dove Medical Press, 2013-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b367d5f7db9940af89a51a0e73a8f8cb
042 |a dc 
100 1 0 |a Wuestenfeld JC  |e author 
700 1 0 |a Wolfarth B  |e author 
245 0 0 |a Special considerations for adolescent athletic and asthmatic patients 
260 |b Dove Medical Press,   |c 2013-01-01T00:00:00Z. 
500 |a 1179-1543 
520 |a Jan C Wuestenfeld,1,2 Bernd Wolfarth1,21Department of Preventive and Rehabilitative Sports Medicine, Technical University Munich (TUM), Munich, Germany; 2Institute for Applied Training Science (IAT), Leipzig, GermanyAbstract: Asthma is defined as a chronic inflammatory disorder of the airways with bronchial hyperresponsiveness and variable bronchoconstriction, and is one of the most common diseases in childhood and adolescence. Exercise-induced asthma-like symptoms and asthma are also frequently seen in highly trained athletes. Exercise-induced asthma (EIA) and exercise-induced bronchoconstriction (EIB) are found in 8%–10% of healthy school-aged children and in 35% of children with asthma. Highly increased ventilation, inhalation of cold, dry air and air pollutants (eg, chlorine) are thought to be important triggers for EIA and EIB. EIA is often experienced concurrently with vocal cord dysfunction, which needs to be considered during the differential diagnosis. The pharmacological treatment of EIA is similar to the treatment of asthma in nonexercising adolescents. The therapy is based on anti-inflammatory drugs (eg, inhaled glucocorticosteroids) and bronchodilators (eg, β2-agonists). The treatment of EIB is comparable to the treatment of EIA and leukotriene modifiers offer a new and promising treatment option, particularly in EIB. Generally, athletes may not use β2-agonists according to the prohibited list of the World Anti-Doping Agency (WADA). However, the WADA list contains specific β2-agonistic substances that are permitted to be used by inhalation.Keywords: exercise-induced asthma, exercise-induced bronchospasm, adolescents, asthma, athletes 
546 |a EN 
690 |a Sports medicine 
690 |a RC1200-1245 
655 7 |a article  |2 local 
786 0 |n Open Access Journal of Sports Medicine, Vol 2013, Iss default, Pp 1-7 (2013) 
787 0 |n http://www.dovepress.com/special-considerations-for-adolescent-athletic-and-asthmatic-patients-a11917 
787 0 |n https://doaj.org/toc/1179-1543 
856 4 1 |u https://doaj.org/article/b367d5f7db9940af89a51a0e73a8f8cb  |z Connect to this object online.